Navigation Links
Indiana University Contracts with Virtify for Clinical Trial Disclosure Solutions
Date:8/19/2013

LEXINGTON, Mass., Aug. 19, 2013 /PRNewswire/ -- Virtify, Inc., a leading innovator in content and regulatory information management solutions for the life science industry, today announced Indiana University has signed an enterprise-level contract for its Clinical Trial Registration & Results (CTRR) disclosure software. Indiana University will utilize Virtify's CTRR to fulfill their regulatory obligations by disclosing their clinical trial information to the National Institute of Health's clinicaltrials.gov system. The system is funded and being implemented by the Indiana Clinical and Translational Sciences Institute (CTSI), a statewide partnership among IU, Purdue University and the University of Notre Dame funded by the National Institutes of Health.

(Logo: http://photos.prnewswire.com/prnh/20110131/NE38689LOGO )

"Indiana CTSI will partner with Virtify to help automate the complex clinical trial disclosure processes within the institution in order to fulfill its regulatory requirements. We're pleased to be working with Virtify to develop solutions that will help to reduce the effort it takes to publish the trial information to clinicaltrials.gov," said Richard Kovacs, M.D., associate dean for clinical research at the Indiana University School of Medicine and associate director of the Indiana CTSI.

The old paradigm for managing disclosure throughout the clinical trial process has changed. In the U.S. alone, submissions to www.clinicaltrials.gov are bound by 2,700 unique rules regarding clinical trial registration and 2,500 additional rules for results postings. Many academic and research organizations manage clinical trial disclosure manually, increasing compliance risk and costs.

Virtify's CTRR streamlines and automates the mandatory registration and clinical results disclosure obligations to the National Institute of Health and other registries. It provides a compliance view across all clinical studies, allowing for better reporting, proactive compliance and patient safety. Virtify CTRR is architected for change. Its unique XML Rules Injection™ technology is designed to provide the speed and flexibility needed to meet all global disclosure requirements while minimizing the overhead and complexity of change management. A detailed CTRR fact sheet is available at http://www.virtify.com/default/assets/File/VirtifyCTRR_Global_Clinical_Trial_Disclosure.pdf .           

"Virtify is very pleased to work with Indiana University. Virtify CTRR will not only help improve compliance but will support the disclosure requirements for publishing to medical journals," said Satish Tadikonda, president and CEO of Virtify, Inc. "Virtify CTRR will eliminate duplicate data entry and will enable Indiana University to have a robust and seamless clinical trial disclosure process."

About the Indiana CTSI

The Indiana CTSI is a statewide collaboration of Indiana University, Purdue University and the University of Notre Dame to facilitate the translation of scientific discoveries in the lab into new patient treatments in Indiana and beyond. It was established in 2008 with a Clinical and Translational Science Award totaling more than $30 million from the National Center for Advancing Translational Science at the National Institutes of Health (Grants TR000006, TR000163 and TR000162; PI: A. Shekhar) with additional support from the state, the three member universities, and public and private partners. It is a member of the national network of 60 CTSA-funded organizations across the country. For more information, visit http://www.indianactsi.org.

About Virtify

Virtify is the leading innovator in content and regulatory information management solutions for life sciences. Many of the world's leading organizations rely on Virtify solutions to reduce time-to-market, risk, and costs by managing and automating the complex regulatory compliance and content exchange requirements throughout the product life cycle. Virtify's life science domain expertise has been leveraged by such companies as Genzyme/Sanofi, Novartis, Pfizer/Wyeth, Regeneron, academic research centers and CROs.  Virtify's easy-to-use software suite is the industry's only solution to provide a secure, collaborative, web-based environment for managing regulated content throughout the entire continuum – from pre-clinical through product registration to commercialization. Visit us at http://www.virtify.com.


'/>"/>
SOURCE Virtify, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioStorage Technologies Mike Reffeitt Named "CFO of the Year" by Indianapolis Business Journal
2. BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector
3. Positron Accepts Economic Incentives Offer From The City Of Gary, Indiana For $30 Million Towards 70 MeV Cyclotron Project
4. Its Indiana State Fair Season: New BioCrossroads Report Emphasizes Opportunities in Food and Agriculture Innovation
5. Indiana’s Life Sciences Industry Economic Impact Tops $50 billion
6. Indigo Biosystems Among “Best Places to Work” in Indiana
7. StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500
8. Nanounity Announces New Characterization Tools for the 2013 Microscopy & Microanalysis Annual Meeting in Indianapolis, August 4-8
9. Arizona State University engineers aim to improve performance of technology in extreme environments
10. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
11. Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots , ... from around the world, was today awarded the "Best Science & Technology Social ... on merit and decided upon by a dedicated team of researchers and analysts. ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... organization with services spanning the full spectrum of drug and device development, and ... services to pharma/device companies and clinicians, today announced Verified Clinical Trials ...
(Date:1/19/2017)... Jan. 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ... immune therapies for operable and inoperable solid tumor cancers, ... Technical Officer of NW Bio, will present at the ... at the Hyatt Regency Hotel in Miami, ... the session entitled "New Therapeutic Approaches – Expanding the ...
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ), a ... live webcast of its Annual Meeting of Shareholders on Tuesday, January ... can be accessed from the BD corporate website at http://www.bd.com/investors/ ... ... BD is a global medical technology company that is ...
Breaking Biology Technology:
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/16/2016)... -- Research and Markets has announced the addition of ... 2021" report to their offering. ... The biometric vehicle access system market, in ... 14.06% from 2016 to 2021. The market is estimated to be ... Million by 2021. The growth of the biometric vehicle access system ...
(Date:12/15/2016)... --  WaferGen Bio-systems, Inc. (NASDAQ: WGBS ... that on December 13, 2016, it received a letter ... Market LLC which acknowledged that, as of December 12, ... had been at $1.00 or greater for ten consecutive ... Rule 5550(a)(2) of the Nasdaq Stock Market. ...
Breaking Biology News(10 mins):